A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer
| Autor: | Baosheng Sun, Shilong Sun, Kuang-Hui Lee, Shuang Xu, Linlin Liu, Mingmei Huangfu, Siyao Li |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Survivin Uterine Cervical Neoplasms Enzyme-Linked Immunosorbent Assay Sensitivity and Specificity Benign tumor Inhibitor of Apoptosis Proteins 03 medical and health sciences 0302 clinical medicine Breast cancer Antigen Antigens Neoplasm Internal medicine medicine Biomarkers Tumor Humans Early Detection of Cancer Autoantibodies Cervical cancer business.industry Case-control study Autoantibody Interleukin-2 Receptor alpha Subunit General Medicine Middle Aged medicine.disease Neoplasm Proteins 030104 developmental biology 030220 oncology & carcinogenesis Case-Control Studies Biomarker (medicine) Female Tumor Suppressor Protein p53 business Precancerous Conditions |
| Zdroj: | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(7) |
| ISSN: | 1423-0380 |
| Popis: | The study was designed to test whether circulating autoantibodies against associated antigens (TAAs) were altered in early cervical cancer and benign cervical tumors. A total of 111 cervical cancer patients, 137 cervical benign tumor patients, and 160 healthy volunteers matched in age were recruited in this study. The expression of autoantibodies was tested using in-house developed enzyme-linked immunosorbent assay (ELISA) with linear peptide envelope antigens derived from TAAs. One-way ANOVA test showed that there was no difference in the CD25 autoantibody expression among the cervical cancer group, benign tumor group, and healthy control group (P = 0.063; P = 0.191). The expression of autoantibodies against survivin and TP53 in the cervical cancer group was significantly higher than that in the benign tumor group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink